Bank of New York Mellon Corp Has $106,000 Stake in Corium International, Inc. (NASDAQ:CORI)
Bank of New York Mellon Corp raised its stake in Corium International, Inc. (NASDAQ:CORI) by 118.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,269 shares of the biopharmaceutical company’s stock after buying an additional 13,683 shares during the period. Bank of New York Mellon Corp’s holdings in Corium International were worth $106,000 as of its most recent SEC filing.
Shares of Corium International, Inc. (NASDAQ:CORI) remained flat at $7.42 during trading on Friday. The company had a trading volume of 70,903 shares. The company has a 50 day moving average price of $8.25 and a 200-day moving average price of $5.65. The stock’s market cap is $265.18 million. Corium International, Inc. has a 12-month low of $2.67 and a 12-month high of $9.57.
Corium International (NASDAQ:CORI) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.13. The firm had revenue of $8.11 million for the quarter, compared to analyst estimates of $8.71 million. Corium International had a negative return on equity of 1,550.00% and a negative net margin of 145.60%. Analysts forecast that Corium International, Inc. will post ($1.69) earnings per share for the current fiscal year.
WARNING: This article was originally published by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/13/bank-of-new-york-mellon-corp-has-106000-stake-in-corium-international-inc-nasdaqcori.html.
Several brokerages have recently issued reports on CORI. BidaskClub downgraded Corium International from a “hold” rating to a “sell” rating in a research report on Friday. Jefferies Group LLC reiterated a “buy” rating and set a $10.00 price objective (up from $8.00) on shares of Corium International in a research report on Monday, August 7th. Zacks Investment Research downgraded Corium International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. WBB Securities upgraded Corium International to a “buy” rating and set a $13.00 price objective for the company in a research report on Friday, July 7th. Finally, ValuEngine upgraded Corium International from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. Corium International has an average rating of “Buy” and an average price target of $11.79.
In other news, major shareholder Life Sciences Maste Perceptive acquired 301,004 shares of the company’s stock in a transaction dated Friday, June 30th. The stock was bought at an average price of $7.71 per share, with a total value of $2,320,740.84. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Perceptive Advisors Llc purchased 1,902,400 shares of the firm’s stock in a transaction dated Thursday, May 25th. The shares were bought at an average cost of $6.25 per share, for a total transaction of $11,890,000.00. The disclosure for this purchase can be found here. Company insiders own 46.50% of the company’s stock.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Want to see what other hedge funds are holding CORI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corium International, Inc. (NASDAQ:CORI).
Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.